Ulcer, Skin
Conditions
Keywords
Skin Ulcer, Acetic Acid, Biofilms
Brief summary
The objective of this clinical trial is to assess the effectiveness of acetic acid in patients suffering from chronic cutaneous ulcers with biofilm. The primary question it seeks to address is whether acetic acid (as a 2% topical solution) is superior to the current standard treatment for chronic cutaneous ulcers with biofilm at our center (Prontosan®). Participants will be randomly assigned to receive either the acetic acid solution treatment or the standard current treatment.
Interventions
DRUGAcetic Acid
The intervention treatment will consist of cleaning with water and soap, application of a compress soaked in 2% dilution of glacial acetic acid (CAS 64-19-7) for 15 minutes, irrigation with distilled water, application of peri-ulcer barrier cream or spray, and the application of ActicoatⓇ on the ulcer bed. Depending on the amount of exudate, more or less alginate will be added as a secondary dressing. A tertiary dressing of polyurethane foam or bandage will be applied according to the area and the nurse's discretion.
DRUGProntosan
The treatment includes ulcer cleansing with water and soap, application of ProntosanⓇ compress for 15 minutes, subsequent irrigation with distilled water, application of peri-ulcer barrier cream or spray, and the application of ActicoatⓇ on the wound bed. More or less alginate will be applied depending on the amount of exudate. A tertiary dressing of polyurethane foam or bandage will be applied according to the area and the nurse's discretion.
Sponsors
Consorci Sanitari de l'Alt Penedès i Garraf
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients over 18 years of age. * Continued care (hospital or outpatient) in one of the Consorci Sanitari Alt Penedes i Garraf (CSAPG) units. * Presence of a cutaneous ulcer with biofilm, with an area of less than 120 cm2, and in any location (except the facial region). * Plan to undergo treatment and follow-up of the lesion (at least 8 weeks) at the study center. * Ability to cooperate in necessary evaluations. * Informed consent for inclusion in the study, either from the participant themselves or from their legal representative.
Exclusion criteria
* Participants diagnosed with any of the following conditions: 1. Ulcers with exposed bone tissue. 2. Neoplastic-origin ulcers. 3. Ulcers lasting more than 18 months. * Participation in another clinical trial involving an experimental intervention during the period of the current trial and/or establishing a visit frequency incompatible with the current trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in ulcer area compared to baseline (percentage) at 8 weeks of treatment | 8 weeks | The assessment of the ulcer will include measuring its area through digital planimetry. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants with ulcer healing at 12 weeks from the start of treatment. | 12 weeks | The assessment of the ulcer will performed by the nurse responsible for monitoring the ulcer. The ulcer will be considered fully healed when the surface is epithelialized. |
| Time (days) to ulcer healing from the start of treatment. | up to 12 weeks | The lesion will be considered fully healed when the surface is epithelialized. This will be confirmed by the nurse responsible for monitoring the lesion. |
| Changes in the wound bed at 8 weeks according to score of section 6 of the RESVECH2.0 (Expected Results of the Assessment and Evaluation of Healing of Chronic Wounds scale. | 8 weeks | The evaluation of changes will be conducted by a trained nurse to apply the RESVECH 2.0 scale. The scores in Section 6 of the RESVECH scale range from 0 to 14. The higher the score, the greater the severity of the injury. |
| Percentage of participants with ulcer healing at 4 weeks from the start of treatment. | 4 weeks | The assessment of the ulcer will performed by the nurse responsible for monitoring the ulcer. The ulcer will be considered fully healed when the surface is epithelialized. |
| The healthcare expenditure associated with each branch of the study | 12 weeks | A descriptive analysis of healthcare expenditure associated with each study branch will be conducted using billing data from the center, which is linked to the insured individual's resource utilization. |
| Change in ulcer area compared to baseline (percentage) at 4 weeks of treatment | 4 weeks | The assessment of the ulcer will include measuring its area through digital planimetry. |
| Change in ulcer area compared to baseline (percentage) at 12 weeks of treatment | 12 weeks | The assessment of the ulcer will include measuring its area through digital planimetry. |
| Number of adverse reactions associated with the treatment, collected from the medical record. | 12 weeks | The number of adverse reactions will be evaluated through the review of the participant's medical records by a trained member of the research team. |
Countries
Spain
Contacts
Primary ContactMarta De Vicente
Backup ContactNoemí Casaponsa
Outcome results
None listed